Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 163,720
- 试验地点
- 1
- 主要终点
- Time to Dementia Onset
研究概览
简要总结
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
详细描述
This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Aged > 65 years on the index date
- •2. For Medicare - Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- •3. At least two claims with hypertension diagnosis recorded in 365 days prior to cohort entry date
排除标准
- •1. Prior history of dementia measured anytime prior to cohort entry date
- •2. Prior use of dihydropyridine CCBs, hydrochlorothiazide, or other antihypertensives anytime prior to cohort entry date
研究组 & 干预措施
Dihydropyridine calcium channel blocker
Exposure group
干预措施: Dihydropyridine calcium channel blocker (Drug)
Hydrochlorothiazide
Reference group
干预措施: Hydrochlorothiazide (Drug)
结局指标
主要结局
Time to Dementia Onset
时间窗: Median follow up times: 1) 189 days (exp), 171 days (ref) 2) 835 days (exp). 851 days (ref) 3) 388 days (exp), 348 days (ref) 4) 191 days (exp), 172 days (ref)
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
次要结局
未报告次要终点
研究者
Rishi J. Desai
Assistant Professor of Medicine
Brigham and Women's Hospital